Nilay Desai, MD
Endocrinology, Diabetes & Metabolism · Rocky Mount, NCNPI 1336157122
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $308,384 of the $360,991 with a category attached, or 85.4%. 18 manufacturers reported payments, led by Novo Nordisk at 47.5% of the total. Reporting peaked in 2019 at $131,386 and has fallen 66.4% since, to $44,097 in 2025. Among endocrinology, diabetes & metabolism clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 520 payments — averaging $694.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$171K
- Lilly USA, LLC$102K
- Boehringer Ingelheim$54K
- Amarin Pharma, Inc.$21K
- Abbott$6K
- Bayer$5K
- plus $1K from 12 others
Across 5 payments — averaging $8996.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$45K
What the payments were for
- Consulting fees$7,1752%
- Speaking & faculty fees$308,38485%
- Travel & lodging$39,00211%
- Food & beverage$6,3042%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 166 | $171,463 |
| Lilly USA, LLC | 179 | $102,493 |
| Boehringer Ingelheim | 89 | $53,571 |
| Amarin Pharma, Inc. | 32 | $20,909 |
| Abbott | 32 | $5,598 |
| Bayer | 6 | $5,499 |
| IBSA Pharma Inc. | 2 | $1,000 |
| Amgen | 1 | $106 |
| Medtronic | 1 | $91 |
| Radius Health, Inc. | 2 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $51 |
| BETA Bionics, Inc. | 1 | $29 |
| Cequr Corporation | 2 | $29 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Insulet Corporation | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Lifescan, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$89,102
- JARDIANCE$83,511
- RYBELSUS$57,948
- TRULICITY$57,111
- Vascepa$20,136
- Tresiba$19,599
- Kerendia$5,422
- FreeStyle Libre Pro$3,575
- Tirosint$1,500
- FreeStyle Libre 2$1,350
- FREESTYLE LIBRE 3$375
- Repatha$106
How this compares
$360,991 in reported general payments places this provider in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 465 | $723,025 |
| JardianceEmpagliflozin | 250 | $255,518 |
| Tresiba Flextouch U-200Insulin Degludec | 208 | $197,021 |
| TrulicityDulaglutide | 121 | $176,026 |
| MounjaroTirzepatide | 103 | $134,513 |
| TradjentaLinagliptin | 126 | $108,821 |
| RybelsusSemaglutide | 71 | $105,907 |
| Gvoke Hypopen 2-PackGlucagon | 144 | $89,540 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 51 | $87,524 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 66 | $86,994 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 81 | $84,002 |
| Humalog Kwikpen U-200Insulin Lispro | 56 | $69,804 |
| JanuviaSitagliptin Phosphate | 68 | $61,146 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 38 | $58,252 |
| FarxigaDapagliflozin Propanediol | 47 | $48,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $171,463 | $845,262601 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $53,571 | $448,341457 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $102,493 | $324,686302 claims |
| AmgenProlia | $106 | $27,62816 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $17 | $22,9351,148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Rocky Mount
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- John BuseChapel Hill$460K
- Denis BeckerRaleigh$459K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.